The budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States.
Sepehr FarahbakhshianTimothy J InocencioGregory PoormanEkaterina WrightRavi Ramesh PathakMichael BullanoPublished in: Journal of medical economics (2022)
BIM results show that increased velaglucerase alfa uptake for GD1 treatment is cost-saving for US health plans.